SCHEMBL3017048

SCHEMBL3017048

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4OC)CC3)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 3/20 0.40
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CNR2 P34972 1/20 0.37
TP53 P04637 3/20 0.36
TSHR P16473 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
MAPK14 Q16539 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007820 0.93 ALDH1A1 (0.41) HTTMAPTSMN1; SMN2MEN1KMT2A
SCHEMBL3016465 0.93 ALDH1A1 (0.42) LMNAHTTMAPTGAASMN1; SMN2
SCHEMBL3018474 0.93 MAPT (0.40) LMNAHTTMAPTSMN1; SMN2TP53
SCHEMBL3018358 0.92 HTT (0.39) LMNAHTTMAPTSMN1; SMN2TP53
SCHEMBL3004540 0.91 CNR2 (0.40) LMNANPSR1MAPTGAASMN1; SMN2
SCHEMBL3017874 0.90 LMNA (0.36) LMNAMAPTGAASMN1; SMN2TP53
SCHEMBL3003698 0.90 CYP3A4 (0.39) LMNAHTTMAPTSMN1; SMN2TP53
SCHEMBL3012043 0.90 ALDH1A1 (0.42) LMNAHTTNPSR1MAPTGAA
SCHEMBL3014929 0.90 MAPK1 (0.39) LMNAHTTMAPTSMN1; SMN2TP53
SCHEMBL3009850 0.89 CNR2 (0.41) MAPTSMN1; SMN2CNR2TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885HTT 2/4885NPSR1 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.